Navigation Links
Bioheart, Inc. Announces Financial Results for Second Quarter 2008
Date:7/30/2008

Development revenues 15,000 - 76,500 -

Expenses:

Research and

development 1,477,634 1,785,661 2,835,691 3,186,251

Marketing, general

and administrative 1,876,442 873,300 2,948,711 1,750,676

Depreciation and

amortization 45,921 45,780 91,549 92,226

Total expenses 3,399,997 2,704,741 5,875,951 5,029,153

Loss from

operations (3,372,732) (2,536,793) (5,764,316) (4,854,760)

Interest income 8,256 75,157 42,202 115,781

Interest expense (496,875) (300,801) (1,430,285) (301,362)

Net interest

(expense) income (488,619) (225,644) (1,388,083) (185,581)

Loss before income

taxes (3,861,351) (2,762,437) (7,152,399) (5,040,341)

Income taxes - - - -

Net loss $(3,861,351) $(2,762,437) $(7,152,399) $(5,040,341)

Loss per share -

basic and diluted $(0.27) $(0.21) $(0.51) $(0.39)

Weighted average shares

outstanding - basic

and diluted 14,447,138 13,235,738 14,150,984 13,012,328

Contact: William Kline Lytham Partners, LLC

Chief Financial Officer Joe Diaz

Nicholas Burke Joe Dorame

VP - Financial Operations Robert Blum

(954) 835-1500 (602) 889-9700


'/>"/>
SOURCE Bioheart, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Bioheart, Inc. to Report Full Year 2007 Financial Results on Thursday, March 27, 2008
2. Bioheart, Inc. Announces Financial Results for First Quarter 2008
3. Bioheart, Inc. Reports Receipt of Notification from NASDAQ Regarding Non-Compliance with Continued Listing Requirements
4. Bioheart, Inc. to Host Annual Meeting of Shareholders on Wednesday, July 30, 2008
5. Bioheart, Inc. to Transfer to Nasdaq Capital Market
6. Bioheart, Inc., Added to Russell Microcap Index
7. Bioheart, Inc., Board Appoints Howard J. Leonhardt Chief Executive Officer
8. Bioheart, Inc. to Introduce At-Home Heart Failure Monitor for Congestive Heart Failure Patients
9. Bioheart, Inc., Announces Management Change
10. Bioheart, Inc. Announces Results of Annual Meeting
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... (PRWEB) May 21, 2015 uBiome, ... announced a partnership with PicnicHealth, a healthcare company ... Participants diagnosed with Inflammatory Bowel Disease (IBD) will ... a complementary uBiome research kit. Both companies were ... , For more information on this ...
(Date:5/21/2015)... , May 21, 2015  CytRx Corporation (NASDAQ: ... company specializing in oncology, today announced positive updated ... with aldoxorubicin for the treatment of unresectable glioblastoma ...  The open-label, multisite trial is designed to investigate ... patients whose tumors have progressed following prior treatment ...
(Date:5/21/2015)... May 21, 2015 Tunnell Consulting, ... the firm as senior statistician and Principal, a position ... experience in the management and analysis of complex and ... chemical industries. , “We’re delighted to have Julia join ... data analytics,” said Dr. Philippe Cini, Group Vice President ...
(Date:5/20/2015)... Pa. , May 20, 2015  Select ... that the Federal Trade Commission granted early termination ... Antitrust Improvements Act of 1976, as amended, applicable ... MJ Acquisition Corporation, a joint venture that Select ... L.P. As previously announced, MJ Acquisition ...
Breaking Biology Technology:uBiome Partners with PicnicHealth 2uBiome Partners with PicnicHealth 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Julia O’Neill Joins Tunnell Consulting’s Operational and Process Improvement Practice 2Select Medical Corporation's Proposed Acquisition of Concentra Inc. through Joint Venture with Welsh Carson Receives Antitrust Clearance 2
... Hill Road in Menlo Park, Calif., which is the venture ... of a "boomlet" in deal-making. Technology firms that only a ... a venture capitalist are now entertaining multiple offers to finance ... company, XenSource, had seven solid investment offers in three weeks. ...
... StrandVision LLC , an online digital signage company, ... supplier in Silverdale, Wash., on Monday announced that they ... agreement, StrandVision resellers and customers will be provided with ... where they will receive information that will help them ...
... in the chemistry department at the University of Wisconsin-Eau ... from the National Science Foundation in recent weeks ... support faculty-student research. , ,"This is a huge influx ... have a significant impact on what we can do ...
Cached Biology Technology:Wisconsin early-stage companies must position themselves to get capital 2Wisconsin early-stage companies must position themselves to get capital 3UW-Eau Claire chemistry faculty get $600,000 in NSF grants 2UW-Eau Claire chemistry faculty get $600,000 in NSF grants 3
(Date:4/17/2015)... April 17, 2015 ... and technological advancement to drive biometric systems market ... 2020   According to a recently ... Systems Market Forecast &  Opportunities, 2020 ", biometric systems market in ... register growth at CAGR of over 22% through ...
(Date:4/13/2015)... 2015 According to a ... Market Forecast & Opportunities, 2020", the global biometrics market ... 14% till 2020. The biometrics market is garnering ... and review of biometric management systems. The constant ... with greater efficiency, are resulting in increasing installation ...
(Date:4/9/2015)... April 9, 2015 Synaptics Inc. (NASDAQ: SYNA ... today that it will report financial results for the ... 2015, after the close of market. The company will ... at 2:00 p.m. PT (5:00 p.m. ET), during which ... participate on the live call, analysts and investors should ...
Breaking Biology News(10 mins):Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2Synaptics to Report Third Quarter Results on April 23 2
... Societies for Experimental Biology (FASEB) announces the opening ... Mechanism and Regulation of Prokaryotic Transcription. ... and Regulation of Prokaryotic Transcription will convene Sunday, ... Transcription Meeting," first held in 1991, has emerged ...
... Since the mid-nineteenth century, maps have helped elucidate the ... Yet today,s global mapping of infectious diseases is considerably ... of potential outbreaks, according to a new systematic mapping ... humans., Of the 355 infectious diseases assessed in the ...
... every time a cell divides and replicates. Depending on ... Many proteins are involved in everyday DNA repair, but ... and cancer can occur. Cells have two complicated ways ... of the entire genome., Roger A. Greenberg, M.D., Ph.D., ...
Cached Biology News:Avoiding a cartography catastrophe 2Changes to DNA on-off switches affect cells' ability to repair breaks, respond to chemotherapy 2
Liquid. PBS containing 10 mM NaN 3 . AVOID FREEZE/THAW CYCLES. Recognizes α1, 2, 3, 5, 6 and 7 subunits of 20S proteasome. ...
Anti-TNKS2 Polyclonal AntibodyOther Sub-Family: not assigned-Other Applications: ELISA, Western Blot...
Rabbit Anti-Human Janus Kinase 2 (JAK2 Polyclonal Antibody Family: Protein Kinase Sub-Family: TYK2/JAK Applications: ELISA, Western Blot...
Goat polyclonal to Lipocalin 2...
Biology Products: